Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0CX0I
|
|||
| Former ID |
DNC013067
|
|||
| Drug Name |
[Dcp1]Dyn A(1-11)-NH2
|
|||
| Synonyms |
CHEMBL412997; [Dcp1]Dyn A(1-11)-NH2
Click to Show/Hide
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C75H117N23O14
|
|||
| Canonical SMILES |
CCC(C)C(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)C(CC3=CC=C(C=C3)O)NC(=O)CCC4=C(C=C(C=C4C)C(=O)N)C
|
|||
| InChI |
1S/C75H117N23O14/c1-7-43(4)62(71(111)95-54(22-15-33-87-75(83)84)72(112)98-34-16-23-58(98)70(110)92-51(64(78)104)19-11-12-30-76)97-67(107)53(21-14-32-86-74(81)82)93-66(106)52(20-13-31-85-73(79)80)94-68(108)55(35-42(2)3)96-69(109)57(38-46-17-9-8-10-18-46)91-61(102)41-88-60(101)40-89-65(105)56(39-47-24-26-49(99)27-25-47)90-59(100)29-28-50-44(5)36-48(63(77)103)37-45(50)6/h8-10,17-18,24-27,36-37,42-43,51-58,62,99H,7,11-16,19-23,28-35,38-41,76H2,1-6H3,(H2,77,103)(H2,78,104)(H,88,101)(H,89,105)(H,90,100)(H,91,102)(H,92,110)(H,93,106)(H,94,108)(H,95,111)(H,96,109)(H,97,107)(H4,79,80,85)(H4,81,82,86)(H4,83,84,87)/t43-,51-,52-,53-,54-,55-,56-,57-,58-,62-/m0/s1
|
|||
| InChIKey |
YPSMIMXFFGKHRC-DJQAJQEISA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor delta (OPRD1) | Target Info | Inhibitor | [1] |
| Opioid receptor kappa (OPRK1) | Target Info | Inhibitor | [1] | |
| Opioid receptor mu (MOP) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| Sphingolipid signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Estrogen signaling pathway | ||||
| Morphine addiction | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Enkephalin release | ||||
| Opioid proenkephalin pathway | ||||
| Opioid proopiomelanocortin pathway | ||||
| Opioid prodynorphin pathway | ||||
| Pathway Interaction Database | IL4-mediated signaling events | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| TCR Signaling Pathway | ||||
| Opioid Signalling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opio... J Med Chem. 2006 Aug 24;49(17):5382-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.